GOSS Stock Forecast & Price Target

Gossamer Bio is attractive because seralutinib shows a differentiated, inhaled, disease-modifying profile in PAH, with management and key opinion leaders viewing the placebo-driven miss as masking a real biological effect rather than indicating lack of efficacy. The evidence package is strengthened by a 13-meter placebo-adjusted 6MWD benefit in PROSERA, positive U.S. and Western Europe data, encouraging CTD-PAH subgroup results, and supportive TORREY and imaging data, while safety concerns appear manageable with monitoring. Financially, the company expects NDA acceptance around end-November/early December to trigger a $125M tranche from its $250M September PIPE, lifting committed proceeds to $150M by year-end and supporting development and launch readiness.

Gossamer Bio is burdened by a weak fundamental setup because seralutinib’s lead Phase 3 PROSERA trial missed its prespecified primary endpoint, leaving FDA approval vulnerable to a Complete Response Letter, an additional study request, or a narrower label. Even with a +13.3 m placebo-adjusted 6MWD gain in the ITT population, the benefit looks modest versus contemporary comparators, while discontinuations were about three times higher than placebo at 15.0% versus 5.8% and adverse events of special interest were 20.5% versus 6.3%. The company also faces heavy commercial and financing risk after Chiesi’s exit, as it must fund development, regulatory review, and eventual launch itself in an increasingly competitive PAH market where uptake depends on payer access, differentiation, and physician confidence.